Integra LifeSciences Holdings
$ 17.10
-3.28%
06 Aug - close price
- Market Cap 1,375,018,000 USD
- Current Price $ 17.10
- High / Low $ 17.73 / 17.05
- Stock P/E N/A
- Book Value 13.41
- EPS -0.09
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE -0.01 %
- 52 Week High 20.49
- 52 Week Low 8.70
About
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, limb reconstruction, orthopedics, and general surgery. The company is headquartered in Princeton, New Jersey.
Analyst Target Price
$19.56
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $6.37 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IART
2026-08-02 13:41:13
This page provides information on Integra Lifesciences Holdings Corp's profit warnings and related financial news. It lists a specific profit warning for FY26 with a revised revenue range. The page also features a compilation of recent news articles concerning Integra LifeSciences, detailing earnings, leadership changes, and FDA clearances.
2026-08-01 01:10:41
This article details Integra LifeSciences' (IART) SEC filings history, emphasizing that these documents are crucial for investors as a primary source of verified financial data. It highlights the company has submitted over 437 documents since 2017, with the most recent being a Form SCHEDULE 13G on July 31, 2026. The article also explains the importance and differences between common SEC filing types like 10-K, 10-Q, 8-K, and Form 4, providing a comprehensive overview for investors tracking IART.
2026-07-31 15:10:58
Vanguard Portfolio Management has disclosed a beneficial ownership of 3,912,816 shares, representing 5.02% of Integra LifeSciences Holdings Corp (IART) common stock, as of June 30, 2026. This Schedule 13G filing indicates Vanguard has sole voting power over 169,723 shares and sole dispositive power over all 3,912,816 shares, with no shared voting or dispositive power. The filing also clarifies that no other single entity has an interest in more than 5% of these reported securities.
2026-07-31 04:42:02
Zacks.com has identified Bassett Furniture Industries (BSET), Aveanna Healthcare Holdings (AVAH), and Integra LifeSciences Holdings (IART) as stocks with breakout potential ahead of August. The article emphasizes identifying stocks within defined trading ranges and highlights the importance of support and resistance levels to spot genuine breakout opportunities. These three companies are recommended based on their Zacks Rank and expected earnings growth rates.
2026-07-31 00:40:55
This article provides a valuation analysis for Integra Lifesciences Holdings Corp (IART), highlighting its current valuation score of 8.05, which ranks 83rd in the Healthcare Equipment & Supplies industry. It details the company's current P/E ratio at -2.58, noting significant deviations from recent highs and lows. The analysis also indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
2026-07-30 13:41:13
This article provides a detailed profile of Integra LifeSciences Holdings Corporation (IART), a global medical technology company. It outlines the company's two main segments, Codman Specialty Surgical (CSS) and Tissue Technologies (TT), and their respective product portfolios. The report also includes company information, key executive details with their shareholdings, and FAQs regarding top shareholders, institutional holdings, and primary revenue sources.
